Scarica l'app Stockscreener
28.76
1.27%
0.36
Dopo l'orario di chiusura:
28.76
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.40
Aprire:
$28.38
Volume 24 ore:
1.75M
Relative Volume:
0.88
Capitalizzazione di mercato:
$2.77B
Reddito:
$522.75M
Utile/perdita netta:
$-558.99M
Rapporto P/E:
-4.4451
EPS:
-6.47
Flusso di cassa netto:
$-439.53M
1 W Prestazione:
+0.17%
1M Prestazione:
-3.43%
6M Prestazione:
-26.93%
1 anno Prestazione:
-49.97%
Intervallo 1D:
$28.05
$29.05
Intervallo di 1 settimana:
$27.88
$29.70
Portata 52W:
$25.81
$57.99
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Confronta RARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
28.76 | 2.74B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light - MSN
Ultragenyx submits BLA for gene therapy for Sanfilippo syndrome - MSN
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Global Healthcare Conference 2025, Sep-23-2025 10 - MarketScreener
Cantor Fitzgerald reiterates Overweight rating on Ultragenyx Pharma stock - Investing.com
Cantor Fitzgerald reiterates Overweight rating on Ultragenyx Pharma stock By Investing.com - Investing.com Australia
Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Voya Investment Management LLC - MarketBeat
Assenagon Asset Management S.A. Acquires 947,865 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Ultragenyx reports positive data on gene therapy for rare disease - MSN
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Pharmaceutical Inc. Grants Restricted Stock Units to New Non-Executive Officers - Quiver Quantitative
Winners Losers: Whats the outlook for Ultragenyx Pharmaceutical Incs sector2025 Key Highlights & AI Powered Market Trend Analysis - khodrobank.com
First Week of May 2026 Options Trading For Ultragenyx Pharmaceutical (RARE) - Nasdaq
Aug Mood: Will Ultragenyx Pharmaceutical Inc outperform tech stocksJuly 2025 Analyst Calls & Risk Controlled Swing Alerts - خودرو بانک
Aug Sentiment: Whats the outlook for Ultragenyx Pharmaceutical Incs sectorJuly 2025 PostEarnings & Expert-Curated Trade Recommendations - خودرو بانک
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials - Investing.com India
Ultragenyx, Mereo in selloff after trial update on bone disorder therapy - MSN
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials By Investing.com - Investing.com Australia
Great Lakes Advisors LLC Lowers Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Risk Check: Can Ultragenyx Pharmaceutical Inc ride the EV waveBond Market & Weekly Breakout Stock Alerts - khodrobank.com
Pattern recognition hints at Ultragenyx Pharmaceutical Inc. upsideJuly 2025 Catalysts & Detailed Earnings Play Strategies - newser.com
Millennium Management LLC Buys 15,157 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx's Glycogen Storage Disease Gene Therapy DTX401 Continues to Enable Decreases in Reductions in Daily Cornstarch Intake at 96 Weeks - cgtlive.com
Aug Drivers: Is Ultragenyx Pharmaceutical Inc stock good for income investorsEarnings Overview Summary & Weekly High Potential Alerts - خودرو بانک
Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity? - Yahoo
Aug Breakouts: Is Ultragenyx Pharmaceutical Inc trading at a discountJuly 2025 Selloffs & Expert Approved Momentum Trade Ideas - خودرو بانک
Fred Alger Management LLC Acquires 58,372 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given Buy Rating at HC Wainwright - MarketBeat
Alliancebernstein L.P. Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Reports Positive Phase 3 Gene Therapy Results - MSN
Ultragenyx Pharmaceutical Inc. $RARE Shares Purchased by Parkman Healthcare Partners LLC - MarketBeat
Ultragenyx Makes Bid for Dimension TherapeuticsBiotech Movers - TheStreet
Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating - TipRanks
121,510 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Cubist Systematic Strategies LLC - MarketBeat
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome - Zacks Investment Research
Ultragenyx releases long-term phase 3 data on gene therapy for metabolic disorder - MSN
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $79 - 富途牛牛
Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments - TipRanks
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.30%
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):